/PRNewswire/ Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization.
Arrowhead Pharmaceuticals, Inc. today announced that it has filed an application for clearance to initiate a Phase 1/2 clinical trial of ARO-DUX4, the company’s investigational RNA interference .
By Chris Wack Arrowhead Pharmaceuticals said Monday that it has filed an application in New Zealand to initiate a Phase 1/2 clinical trial of ARO-DUX4, its.
PASADENA, Calif. (BUSINESS WIRE) $arwr Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has filed an application for clearance to initiate a Phase 1/2 clinical trial of ARO-DUX4, the company’s investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for pa.